Literature DB >> 29325707

Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment.

Herve Tiriac1, Juan Carlos Bucobo2, Demetrios Tzimas2, Suman Grewel2, Joseph F Lacomb2, Leahana M Rowehl2, Satish Nagula2, Maoxin Wu3, Joseph Kim4, Aaron Sasson4, Shivakumar Vignesh5, Laura Martello5, Maria Munoz-Sagastibelza5, Jonathan Somma6, David A Tuveson1, Ellen Li2, Jonathan M Buscaglia2.   

Abstract

BACKGROUND AND AIMS: Pancreatic cancer organoids are tumor models of individualized human pancreatic ductal adenocarcinoma (PDA), created from surgical specimens and used for personalized treatment strategies. Unfortunately, most patients with PDA are not operative candidates. Creation of human PDA organoids at the time of initial tumor diagnosis is therefore critical. Our aim was to assess the feasibility of creating human PDA organoids by EUS fine-needle biopsy (EUS-FNB) sampling in patients with PDA.
METHODS: In this prospective clinical trial in patients referred to evaluate a pancreatic mass, EUS-FNA was performed for initial onsite diagnosis. Two additional needle passes were performed with a 22-gauge FNB needle for organoid creation. Primary outcome was successful isolation of organoids within 2 weeks of EUS-FNB sampling (P0, no passages), confirmed by organoid morphology and positive genotyping.
RESULTS: Thirty-seven patients with 38 PDA tumors were enrolled. Successful isolation of organoids (P0) was achieved in 33 of 38 tumors (87%). Establishment of PDA organoid lines for ≥5 passages of growth (P5, five passages) was reached in 25 of 38 tumors (66%). In the single patient with successful P5 FNB sampling-derived and P5 surgically derived organoids, there was identical matching of specimens. There were no serious adverse events. Two patients developed bleeding at the EUS-FNB puncture site requiring hemostasis clips.
CONCLUSIONS: Pancreatic cancer organoids can be successfully and rapidly created by means of EUS-FNB sampling using a 22-gauge needle at the time of initial diagnosis. Successful organoid generation is essential for precision medicine in patients with pancreatic cancer in whom most are not surgically resectable. (Clinical trial registration number: NCT03140592.).
Copyright © 2018 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29325707      PMCID: PMC6143289          DOI: 10.1016/j.gie.2017.12.032

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  28 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.

Authors:  Shuanzeng Wei; David Lieberman; Jennifer J D Morrissette; Zubair W Baloch; David B Roth; Cindy McGrath
Journal:  Cancer Cytopathol       Date:  2015-12-18       Impact factor: 5.284

3.  Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.

Authors:  Michael P Kim; Douglas B Evans; Huamin Wang; James L Abbruzzese; Jason B Fleming; Gary E Gallick
Journal:  Nat Protoc       Date:  2009-10-29       Impact factor: 13.491

Review 4.  Endoscopic ultrasonography-guided tissue acquisition: How to achieve excellence.

Authors:  Vikram Bhatia; Shyam Varadarajulu
Journal:  Dig Endosc       Date:  2017-03-22       Impact factor: 7.559

5.  An in vivo platform for translational drug development in pancreatic cancer.

Authors:  Belen Rubio-Viqueira; Antonio Jimeno; George Cusatis; Xianfeng Zhang; Christine Iacobuzio-Donahue; Collins Karikari; Chanjusn Shi; Kathleen Danenberg; Peter V Danenberg; Hidekazu Kuramochi; Koji Tanaka; Sharat Singh; Hossein Salimi-Moosavi; Nadia Bouraoud; Maria L Amador; Soner Altiok; Piotr Kulesza; Charles Yeo; Wells Messersmith; James Eshleman; Ralph H Hruban; Anirban Maitra; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

6.  Model organoids provide new research opportunities for ductal pancreatic cancer.

Authors:  Sylvia F Boj; Chang-Il Hwang; Lindsey A Baker; Dannielle D Engle; David A Tuveson; Hans Clevers
Journal:  Mol Cell Oncol       Date:  2015-02-23

Review 7.  A meta-analysis comparing ProCore and standard fine-needle aspiration needles for endoscopic ultrasound-guided tissue acquisition.

Authors:  Ji Young Bang; Robert Hawes; Shyam Varadarajulu
Journal:  Endoscopy       Date:  2015-11-12       Impact factor: 10.093

Review 8.  Fine-needle biopsy: should this be the first choice in endoscopic ultrasound-guided tissue acquisition?

Authors:  Eun Young Kim
Journal:  Clin Endosc       Date:  2014-09-30

9.  Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.

Authors:  Daniel Öhlund; Abram Handly-Santana; Giulia Biffi; Ela Elyada; Ana S Almeida; Mariano Ponz-Sarvise; Vincenzo Corbo; Tobiloba E Oni; Stephen A Hearn; Eun Jung Lee; Iok In Christine Chio; Chang-Il Hwang; Hervé Tiriac; Lindsey A Baker; Dannielle D Engle; Christine Feig; Anne Kultti; Mikala Egeblad; Douglas T Fearon; James M Crawford; Hans Clevers; Youngkyu Park; David A Tuveson
Journal:  J Exp Med       Date:  2017-02-23       Impact factor: 14.307

Review 10.  Organoids: A historical perspective of thinking in three dimensions.

Authors:  Marina Simian; Mina J Bissell
Journal:  J Cell Biol       Date:  2016-12-28       Impact factor: 10.539

View more
  56 in total

Review 1.  Organoid models for translational pancreatic cancer research.

Authors:  Hervé Tiriac; Dennis Plenker; Lindsey A Baker; David A Tuveson
Journal:  Curr Opin Genet Dev       Date:  2019-03-04       Impact factor: 5.578

2.  Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Francisca Beato; Dayana Reverón; Kaleena B Dezsi; Antonio Ortiz; Joseph O Johnson; Dung-Tsa Chen; Karla Ali; Sean J Yoder; Daniel Jeong; Mokenge Malafa; Pamela Hodul; Kun Jiang; Barbara A Centeno; Mahmoud A Abdalah; Jodi A Balasi; Alexandra F Tassielli; Bhaswati Sarcar; Jamie K Teer; Gina M DeNicola; Jennifer B Permuth; Jason B Fleming
Journal:  Lab Invest       Date:  2020-10-09       Impact factor: 5.662

3.  Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology.

Authors:  Zahra Dantes; Hsi-Yu Yen; Nicole Pfarr; Christof Winter; Katja Steiger; Alexander Muckenhuber; Alexander Hennig; Sebastian Lange; Thomas Engleitner; Rupert Öllinger; Roman Maresch; Felix Orben; Irina Heid; Georgios Kaissis; Kuangyu Shi; Geoffrey Topping; Fabian Stögbauer; Matthias Wirth; Katja Peschke; Aristeidis Papargyriou; Massoud Rezaee-Oghazi; Karin Feldmann; Arlett Pg Schäfer; Raphela Ranjan; Clara Lubeseder-Martellato; Daniel E Stange; Thilo Welsch; Marc Martignoni; Güralp O Ceyhan; Helmut Friess; Alexander Herner; Lucia Liotta; Matthias Treiber; Guido von Figura; Mohamed Abdelhafez; Peter Klare; Christoph Schlag; Hana Algül; Jens Siveke; Rickmer Braren; Gregor Weirich; Wilko Weichert; Dieter Saur; Roland Rad; Roland M Schmid; Günter Schneider; Maximilian Reichert
Journal:  JCI Insight       Date:  2020-08-06

4.  Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.

Authors:  Joseph E Grossman; Lakshmi Muthuswamy; Ling Huang; Dipikaa Akshinthala; Sofia Perea; Raul S Gonzalez; Leo L Tsai; Jonah Cohen; Bruno Bockorny; Andrea J Bullock; Benjamin Schlechter; Mary Linton B Peters; Catherine Conahan; Supraja Narasimhan; Christine Lim; Roger B Davis; Robert Besaw; Mandeep S Sawhney; Douglas Pleskow; Tyler M Berzin; Martin Smith; Tara S Kent; Mark Callery; Senthil K Muthuswamy; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 12.531

5.  Patient-Derived Sarcoma Organoids Offer a Novel Platform for Personalized Precision Medicine.

Authors:  Adrian Sanchez-Fdez; Ashwyn K Sharma; Herve Tiriac; Jason K Sicklick
Journal:  Ann Surg Oncol       Date:  2022-07-13       Impact factor: 4.339

6.  Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer.

Authors:  Mirunalini Ravichandran; Jingjie Hu; Charles Cai; Nathan P Ward; Anthony Venida; Callum Foakes; Miljan Kuljanin; Annan Yang; Connor J Hennessey; Yang Yang; Brandon R Desousa; Gilles Rademaker; Annelot A L Staes; Zeynep Cakir; Isha H Jain; Andrew J Aguirre; Joseph D Mancias; Yin Shen; Gina M DeNicola; Rushika M Perera
Journal:  Cancer Discov       Date:  2022-09-02       Impact factor: 38.272

7.  Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.

Authors:  Mei Gao; Megan M Harper; Miranda Lin; Shadi A Qasem; Reema A Patel; Samuel H Mardini; Moamen M Gabr; Michael J Cavnar; Prakash K Pandalai; Joseph Kim
Journal:  J Am Coll Surg       Date:  2020-11-27       Impact factor: 6.113

Review 8.  Can Pancreatic Organoids Help in the Treatment of Pancreatic Cancer?

Authors:  Toni T Seppälä; Richard A Burkhart
Journal:  Adv Surg       Date:  2021-07-06

Review 9.  Organoid models of gastrointestinal cancers in basic and translational research.

Authors:  Harry Cheuk Hay Lau; Onno Kranenburg; Haipeng Xiao; Jun Yu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-25       Impact factor: 46.802

Review 10.  Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?

Authors:  John Kokkinos; Anya Jensen; George Sharbeen; Joshua A McCarroll; David Goldstein; Koroush S Haghighi; Phoebe A Phillips
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.